Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAY 3401016 Phase 2a study in adults with Alport syndrome
2024-516471-33-00Phase 2Authorised
- Sponsor
- Bayer
- Start
- Jan 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 15
01
Overview
Phase 2, randomised, double-blind trial in Alport syndrome comparing BAY 3401016 with Placebo (2 arms). Primary endpoint: Mean UACR ratio to baseline averaged over 16, 20 and 24 weeks of treatment. Planned start Jan 2026; status: authorised.
02
Drugs
BAY 3401016
03
Conditions
Alport syndrome
Beyond the preview
Go deeper on 2024-516471-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516471-33-00.